HK1020017A1 - Therapeutic treatment for vegf related occular diseases. - Google Patents

Therapeutic treatment for vegf related occular diseases.

Info

Publication number
HK1020017A1
HK1020017A1 HK99105357A HK99105357A HK1020017A1 HK 1020017 A1 HK1020017 A1 HK 1020017A1 HK 99105357 A HK99105357 A HK 99105357A HK 99105357 A HK99105357 A HK 99105357A HK 1020017 A1 HK1020017 A1 HK 1020017A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic treatment
vegf related
occular diseases
occular
diseases
Prior art date
Application number
HK99105357A
Other languages
English (en)
Inventor
Lloyd P Aiello
Michael R Jirousek
George L King
Louis Vignati
Douglas Kirk Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1020017A1 publication Critical patent/HK1020017A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK99105357A 1996-05-01 1999-11-19 Therapeutic treatment for vegf related occular diseases. HK1020017A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,739 US6114320A (en) 1996-05-01 1997-04-30 Therapeutic treatment for VEGF related ocular diseases
PCT/US1997/007800 WO1997040831A1 (en) 1996-05-01 1997-05-01 Therapeutic treatment for vegf related occular diseases

Publications (1)

Publication Number Publication Date
HK1020017A1 true HK1020017A1 (en) 2000-03-10

Family

ID=26688915

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99105357A HK1020017A1 (en) 1996-05-01 1999-11-19 Therapeutic treatment for vegf related occular diseases.

Country Status (22)

Country Link
US (1) US6114320A (ru)
EP (1) EP0918519B1 (ru)
JP (1) JP4122060B2 (ru)
KR (1) KR100364487B1 (ru)
CN (1) CN1158073C (ru)
AT (1) ATE270548T1 (ru)
AU (1) AU724923B2 (ru)
BR (1) BR9710705A (ru)
CA (1) CA2253613C (ru)
CZ (1) CZ296711B6 (ru)
DE (1) DE69729798T2 (ru)
EA (1) EA001752B1 (ru)
ES (1) ES2224249T3 (ru)
HK (1) HK1020017A1 (ru)
HU (1) HU226378B1 (ru)
IL (1) IL126836A (ru)
NO (1) NO322209B1 (ru)
NZ (2) NZ332833A (ru)
PL (1) PL189020B1 (ru)
PT (1) PT918519E (ru)
UA (1) UA54427C2 (ru)
WO (1) WO1997040831A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
ATE371453T1 (de) * 1998-08-13 2007-09-15 Novartis Pharma Gmbh Verfahren zur behandlung von okularen neovaskularen erkrankungen
US6214819B1 (en) 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
DK1131073T3 (da) * 1998-11-23 2004-02-02 Novartis Ag Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
JP4731016B2 (ja) * 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
BR0108085A (pt) 2000-02-07 2003-03-18 Abbott Gmbh & Co Kg Derivados de 2-benzotiazolil uréia e seu uso como inibidores da cinase protéica
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
CA2492989C (en) * 2002-07-23 2012-11-20 Novartis Ag Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
WO2004112796A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
NZ550340A (en) * 2004-03-17 2010-08-27 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle using a retinoid
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
RU2009110257A (ru) * 2006-08-23 2010-09-27 Новартис АГ (CH) Применение ингибиторов ркс, прежде всего производных индолилмалеимида для лечения глазных заболеваний
WO2008042399A2 (en) * 2006-10-03 2008-04-10 The Trustees Of The University Of Pennsylvania Method for treatment of macular degeneration
CA2981021C (en) 2015-03-26 2020-11-17 Eyekor, Llc Image analysis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
IL111851A (en) * 1993-12-07 1998-09-24 Lilly Co Eli Improved synthesis of bisindolylsimilides and process for its preparation
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
NO322209B1 (no) 2006-08-28
CA2253613C (en) 2007-11-27
CZ296711B6 (cs) 2006-05-17
JP4122060B2 (ja) 2008-07-23
CN1158073C (zh) 2004-07-21
KR100364487B1 (ko) 2003-01-25
EA001752B1 (ru) 2001-08-27
AU724923B2 (en) 2000-10-05
HUP9902805A2 (hu) 2000-02-28
WO1997040831A1 (en) 1997-11-06
PL189020B1 (pl) 2005-06-30
CZ349998A3 (cs) 1999-11-17
ES2224249T3 (es) 2005-03-01
EP0918519A1 (en) 1999-06-02
KR20000065172A (ko) 2000-11-06
HUP9902805A3 (en) 2000-04-28
NO985067L (no) 1998-12-22
JP2000514402A (ja) 2000-10-31
EP0918519B1 (en) 2004-07-07
PT918519E (pt) 2004-10-29
IL126836A0 (en) 1999-09-22
ATE270548T1 (de) 2004-07-15
HU226378B1 (en) 2008-10-28
AU2936197A (en) 1997-11-19
EP0918519A4 (en) 1999-08-11
US6114320A (en) 2000-09-05
NZ538109A (en) 2006-10-27
DE69729798D1 (de) 2004-08-12
NO985067D0 (no) 1998-10-30
DE69729798T2 (de) 2005-08-25
IL126836A (en) 2004-05-12
CA2253613A1 (en) 1997-11-06
UA54427C2 (ru) 2003-03-17
NZ332833A (en) 2000-07-28
CN1222850A (zh) 1999-07-14
PL330463A1 (en) 1999-05-24
EA199800970A1 (ru) 1999-06-24
BR9710705A (pt) 1999-08-17

Similar Documents

Publication Publication Date Title
HK1020017A1 (en) Therapeutic treatment for vegf related occular diseases.
UA84665C2 (ru) Способ ингибирования опосредствованного ангиогенеза в ткани у пациента с неоваскулярным заболеванием роговицы
EA199800971A1 (ru) Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с
NO20000087L (no) Behandling av inflammatoriske sykdommer i tarmen og urinblære
ATE315933T1 (de) Therapeutische behandlung von kardiovaskularen krankheiten
PT829262E (pt) Utilizacao de inibidores de pkc para o fabrico de um medicamento para o tratamento de disfuncoes sexuais.
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
NO990949L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
EP0940142A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon
NO990948L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner
US5721216A (en) Treatment of diseases caused by parasitic protozoa and fungal diseases by administration of 5-deoxy-5-(substituted) ethylthioribose compounds
HUP9903911A2 (hu) PKC inhibitorok alkalmazása a központi idegrendszer HIV-fertőzéssel kapcsolatos megbetegedéseinek kezelésére szolgáló gyógyászati készítmények előállítására

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120501